The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Randomized Trial of Clazosentan in Patients With Aneurysmal Subarachnoid Hemorrhage Undergoing Endovascular Coiling
Open accessAbstract
Background and Purpose—: Clazosentan, an endothelin receptor antagonist, has been shown to reduce vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). CONSCIOUS-3 assessed whether clazosentan reduced vasospasm-related morbidity and all-cause mortality postaSAH secured by endovascular coiling. Methods—: This double-blind, placebo-controlled, phase III trial randomized patients with aSAH secured by endovascular coiling to ≤14 days intravenous clazosentan (5 or 15 mg/h) or placebo. The primary composite end point (all-cause mortality; vasospasm-related new cerebral infarcts or delayed ischemic neurological deficits; rescue therapy for vasospasm) was evaluated 6 weeks postaSAH. The main secondary end point was dichotomized extended Glasgow Outcome Scale (week 12). Results—: CONSCIOUS-3 was halted prematurely following completion of CONSCIOUS-2; 577/1500 of planned patients (38%) were enrolled and 571 were treated (placebo, n=189; clazosentan 5 mg/h, n=194; clazosentan 15 mg/h, n=188). The primary end point occurred in 50/189 of placebo-treated patients (27%), compared with 47/194 patients (24%) treated with clazosentan 5 mg/h (odds ratio [OR], 0.786; 95% CI, 0.479–1.289; P= 0.340), and 28/188 patients (15%) treated with clazosentan 15 mg/h (OR, 0.474; 95% CI, 0.275–0.818; P= 0.007). Poor outcome (extended Glasgow Outcome Scale score ≤4) occurred in 24% of patients with placebo, 25% of patients with clazosentan 5 mg/h (OR, 0.918; 95% CI, 0.546–1.544; P= 0.748), and 28% of patients with clazosentan 15 mg/h (OR, 1.337; 95% CI, 0.802–2.227; P= 0.266). Pulmonary complications, anemia, and hypotension were more common in patients who received clazosentan than in those who received placebo. At week 12, mortality was 6%, 4%, and 6% with placebo, clazosentan 5 mg/h, and clazosentan 15 mg/h, respectively. Conclusions—: Clazosentan 15 mg/h significantly reduced postaSAH vasospasm-related morbidity/all-cause mortality; however, neither dose improved outcome (extended Glasgow Outcome Scale). Clinical Trial Registration—: URL: http://clinicaltrials.gov . Unique identifier: NCT00940095.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WILSON, J. T. L., PETTIGREW, L. E. L., & TEASDALE, G. M. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.573 · Cited by 2,386
Bederson, J. B., Connolly, E. S., Batjer, H. H., Dacey, R. G., Dion, J. E., Diringer, M. N., Duldner, J. E., Harbaugh, R. E., Patel, A. B., & Rosenwasser, R. H. (2009) · Stroke · doi:10.1161/strokeaha.108.191395 · Cited by 1,189
Calcium antagonists for aneurysmal subarachnoid haemorrhage
Dorhout Mees, S., Rinkel, G. J., Feigin, V. L., Algra, A., van den Bergh, W. M., Vermeulen, M., & van Gijn, J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000277.pub3 · Cited by 758
Macdonald, R. L., Kassell, N. F., Mayer, S., Ruefenacht, D., Schmiedek, P., Weidauer, S., Frey, A., Roux, S., & Pasqualin, A. (2008) · Stroke · doi:10.1161/strokeaha.108.519942 · Cited by 648
Self-citationMacdonald, R. L., Higashida, R. T., Keller, E., Mayer, S. A., Molyneux, A., Raabe, A., Vajkoczy, P., Wanke, I., Bach, D., Frey, A., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70108-9 · Cited by 644
Self-citationDreier, J. P., Major, S., Manning, A., Woitzik, J., Drenckhahn, C., Steinbrink, J., Tolias, C., Oliveira-Ferreira, A. I., Fabricius, M., Hartings, J. A., et al. (2009) · Brain · doi:10.1093/brain/awp102 · Cited by 545
Self-citationCerebral vasospasm after subarachnoid hemorrhage: the emerging revolution
Macdonald, R. L., Pluta, R. M., & Zhang, J. H. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0490 · Cited by 397
Self-citationFunctional Outcome Measures in Contemporary Stroke Trials
Quinn, T. J., Dawson, J., Walters, M. R., & Lees, K. R. (2009) · International Journal of Stroke · doi:10.1111/j.1747-4949.2009.00271.x · Cited by 397
Utility of the NIH Stroke Scale as a Predictor of Hospital Disposition
Schlegel, D., Kolb, S. J., Luciano, J. M., Tovar, J. M., Cucchiara, B. L., Liebeskind, D. S., & Kasner, S. E. (2003) · Stroke · doi:10.1161/01.str.0000048217.44714.02 · Cited by 362
Underlying Structure of the National Institutes of Health Stroke Scale: Results of a Factor Analysis
Lyden, P., Lu, M., Jackson, C., Marler, J., Kothari, R., Brott, T., & Zivin, J. (1999) · Stroke · doi:10.1161/01.str.30.11.2347 · Cited by 354
Cited by
Delayed neurological deterioration after subarachnoid haemorrhage
Macdonald, R. L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.246 · Cited by 887
Self-citationControversies and evolving new mechanisms in subarachnoid hemorrhage
Chen, S., Feng, H., Sherchan, P., Klebe, D., Zhao, G., Sun, X., Zhang, J., Tang, J., & Zhang, J. H. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.09.002 · Cited by 344
Pathophysiology of Delayed Cerebral Ischemia After Subarachnoid Hemorrhage: A Review
Dodd, W. S., Laurent, D., Dumont, A. S., Hasan, D. M., Jabbour, P. M., Starke, R. M., Hosaka, K., Polifka, A. J., Hoh, B. L., & Chalouhi, N. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021845 · Cited by 315
Geraghty, J. R., & Testai, F. D. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0690-x · Cited by 304
Endothelin: 30 Years From Discovery to Therapy
Barton, M., & Yanagisawa, M. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12105 · Cited by 295
Metadata
- Authors
- Macdonald, R. L., Higashida, R. T., Keller, E., Mayer, S. A., Molyneux, A., Raabe, A., Vajkoczy, P., Wanke, I., Bach, D., Frey, A., Nowbakht, P., Roux, S., & Kassell, N.
- Venue
- Stroke
- Published
- 2012-06
- Volume
- 43
- Issue
- 6
- Pages
- 1463-1469
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2027913805
- Cited by
- 344
- References
- 14
- FWCI
- 12.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Trial of Clazosentan in Patients With Aneurysmal Subarachnoid Hemorrhage Undergoing Endovascular Coiling. https://app.cochat.ai/papers/10.1161/strokeaha.111.648980
- The paper
- Macdonald, R. L., Higashida, R. T., Keller, E., Mayer, S. A., Molyneux, A., Raabe, A., Vajkoczy, P., Wanke, I., Bach, D., Frey, A., Nowbakht, P., Roux, S., & Kassell, N. (2012). Randomized Trial of Clazosentan in Patients With Aneurysmal Subarachnoid Hemorrhage Undergoing Endovascular Coiling. Stroke. https://doi.org/10.1161/strokeaha.111.648980
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.